Transgene SA

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

10 Sep 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

09 Sep 2024 01:00:00 By Nasdaq GlobeNewswire

Transgene to Participate in HTID Conference and Investor Access Forum in Paris

05 Sep 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC

27 Aug 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024

22 Jul 2024 02:00:00 By Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024

10 Jul 2024 12:00:00 By Nasdaq GlobeNewswire

Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer

03 Jun 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene’s Combined General Meeting of May 15, 2024

15 May 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene provides business and financial update for Q1 2024

14 May 2024 11:45:00 By Nasdaq GlobeNewswire

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024

24 Apr 2024 11:45:00 By Nasdaq GlobeNewswire

Availability of Transgene's 2023 Universal Registration Document

11 Apr 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

09 Apr 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

27 Mar 2024 12:45:00 By Nasdaq GlobeNewswire

Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

27 Mar 2024 12:45:00 By Nasdaq GlobeNewswire

Transgene Announces Upcoming Investor Meetings

18 Mar 2024 12:45:00 By Nasdaq GlobeNewswire

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

06 Mar 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

05 Mar 2024 01:30:00 By Nasdaq GlobeNewswire

Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

22 Jan 2024 11:45:00 By Nasdaq GlobeNewswire

Transgene Announces Financial Calendar for 2024

22 Jan 2024 02:00:00 By Nasdaq GlobeNewswire

Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

08 Jan 2024 11:45:00 By Nasdaq GlobeNewswire